Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
ARGX vs SYRE — Stock Comparison
Compare ARGX and SYRE side-by-side on StoQuant: ARGX Q-Score 64 vs SYRE 53; analyst signal 53 vs 40. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- ARGX — argenx SE · Health Care · market cap $49.77B · Q-Score verdict Buy (64.0, grade B) · analyst signal 53/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 89/100, valuation 50/100 · weakest signals: analyst consensus 23/100. Full ARGX research.
- SYRE — Spyre Therapeutics Inc. Common Stock · Health Care · Q-Score verdict Hold (53.0, grade C) · analyst signal 40/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: valuation 75/100, technicals 72/100 · weakest signals: competitive moat 12/100, analyst consensus 5/100. Full SYRE research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: ARGX research · SYRE research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.